Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05210374 · ClinicalTrials.gov registry record · Phase 1
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
A Phase 1 study of Relapsed Sarcomas, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05210374 is a Phase 1 study of Relapsed Sarcomas that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05210374, a Phase 1 study of Relapsed Sarcomas, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
Conditions Studied
Interventions
- DRUG Disulfiram
- DRUG Copper Gluconate
- DRUG Liposomal Doxorubicin (Doxil)
Study Locations (1)
Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-03-09 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05210374
The ClinicalTrials.gov registry entry for NCT05210374 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed Sarcomas appearing as the primary indexed condition, and to 3 interventions - of which Disulfiram is the first listed.
NCT05210374 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05210374 about?
NCT05210374 is a clinical study titled "Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas". The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
What is the current status of trial NCT05210374?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-03-09. Estimated completion is 2026-12-31.
What conditions does trial NCT05210374 study?
This clinical trial studies the following conditions: Relapsed Sarcomas.
What interventions are being tested in trial NCT05210374?
The interventions under investigation include: Disulfiram (DRUG), Copper Gluconate (DRUG), Liposomal Doxorubicin (Doxil) (DRUG).
Who is sponsoring clinical trial NCT05210374?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05210374 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.